Oncothyreon Reports Full Year and Fourth Quarter 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Jefferies Starts Oncothyreon (ONTY) at Buy; Sees 49% Upside
March 12, 2015 6:42 AM EDTJefferies initiates coverage on Oncothyreon (NASDAQ: ONTY) with a Buy rating and a price target of $2.50, suggesting 49% upside to yesterday's close.
Analyst Biren Amin commented, "ONTY's ONT-380 has shown encouraging efficacy in PI trials and differentiates itself from competitors on safety. ONTY is further... More
Oncothyreon (ONTY) Misses Q4 EPS by 21c
March 10, 2015 4:02 PM EDTOncothyreon (NASDAQ: ONTY) reported Q4 EPS of ($0.30), $0.21 worse than the analyst estimate of ($0.09).
As of December 31, 2014, Oncothyreon's cash, cash equivalents and investments were $63.7 million, compared to $72.6 million at December 31, 2013, a decrease of $8.9 million, or 12.3 percent. The decrease was primarily attributable to $48.4... More
